Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Mantle Cell Lymphoma Clinical Trial

— FIL_KLIMT  

Official title:

Carfilzomib (K) Plus Lenalidomide (R) and Dexamethasone (D) for BTK Inhibitors Relapsed-refractory or Intolerant Mantle Cell Lymphomas: a Phase II Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03891355
• Other study ID #: FIL_KLIMT
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: September 30, 2019
• Est. completion date: December 8, 2022

Study information

• Verified date: September 2022
• Source: Fondazione Italiana Linfomi ONLUS
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multicenter, single arm, phase II trial designed to evaluate activity and the safety of the combination of Carfilzomib (K), Lenalidomide (R) and Dexamethasone (D) in patients with mantle cell lymphoma (MCL) relapsed/refractory (R/R) or intolerant to BTK inhibitor (BTKi) monotherapy or BTKi containing regimens with active disease necessitating treatment.

Description:

This is a prospective, multicenter, single arm, phase II trial designed to evaluate the safety and efficacy of the combination of Carfilzomib (K), Lenalidomide (R) and Dexamethasone (D) in patients with mantle cell lymphoma (MCL) relapsed/refractory (R/R) or intolerant to BTK inhibitor (BTKi) monotherapy or BTKi containing regimens. The primary endpoint will be assessed 12 months after the start of treatment of the last patient. However, responsive patients (CR, PR, SD) may continue to receive K up to a maximum of 24 cycles and RD up to a maximum of 24 cycles. Patients who will interrupt therapy (for any reason) will be followed up to 12 months after the end of the treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 16
• Est. completion date: December 8, 2022
• Est. primary completion date: December 4, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion criteria Patient has a confirmed diagnosis of MCL according to the WHO 2017 classification;

• Previous treatment with BTKi monotherapy or BTKi containing regimens with R/R disease; and/or patients who discontinued BTKi monotherapy or BTKi containing regimens for adverse events and have active disease necessitating treatment;
• Previous treatment with Lenalidomide is accepted if patient resulted responsive and interrupted Lenalidomide at least 12 months before enrollment to this study;
• Patient age is = 18 < 80 years;
• Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of = 2;
• Understands and voluntarily signs an informed consent form;
• Able to adhere to the study visit schedule and other protocol requirements; Patient has at least one site of measurable nodal disease at baseline = 2.0 cm in the longest transverse diameter as determined by CT scan (MRI is allowed only if CT scan cannot be performed). Note: Patients with bone marrow involvement are eligible;
• Adequate hematological counts: ANC > 1.5 x 109/L and platelet count > 75 x 109/L unless due to bone marrow involvement by MCL;
• Conjugated bilirubin up to 2 x ULN unless due to liver involvement by MCL;
• Alkaline phosphatase and transaminases up to 2 x ULN unless due to liver involvement by MCL;
• Creatinine clearance = 30 ml/min; a dose reduction of Lenalidomide for patients with creatinine clearance = 30 mL/min but < 50 mL/min is planned;
• Patient has the ability to swallow capsules or tablets;
• Life expectancy = 2 months;
• Male and Female patients: accordance to comply with Lenalidomide Risk Management Plan for pregnancy prevention. Exclusion criteria
• Patient who have received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study;
• Patient has a history of CNS involvement with lymphoma;
• Patient with previous history of malignancies (apart MCL) = 3 years before study accrual with the exception of currently treated basal cell and squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix;
• History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances;
• Patient has any other concurrent severe and/or uncontrolled medical condition(s) (e.g., uncontrolled diabetes mellitus, uncontrolled hypertension, active/symptomatic coronary artery disease, chronic obstructive pulmonary disease (COPD), active hemorrhage, psychiatric illness, active or uncontrolled infection that in the investigator opinion places the patient at unacceptable risk and would prevent the subject from signing the informed consent form;
• Creatinine clearance < 30 ml/min;
• Significant neuropathy (Grades 3 - 4, or Grade 2 with pain) within 14 days prior to enrollment;
• Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize Carfilzomib);
• Contraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment;
• Patients with LVEF <40%
• Patients with New York Health Association (NYHA) Class III and IV heart failure; myocardial infarction in the preceding 6 months; conduction abnormalities, including but not limited to atrial fibrillation, atrioventricular (AV) block, QT prolongation, sick sinus syndrome, ventricular tachycardia;
• Patients with severe bradycardia (heart rate <40 bpm, hypotension, light-headedness, syncope);
• Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrollment;
• Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of study enrollment);
• Patient has a known history of HIV seropositivity;
• Patient has active HBV hepatitis. The following categories of HBV positive patients

but with no evidence of active hepatitis may be considered for the study:

• patient is HBsAg + with HBV DNA < 2000 UI/ml (inactive carriers); HBV DNA > 2000 UI/ml is criteria of exclusion;
• patient is HBsAg - HBsAb +;
• patient is HBsAg - but HBcAb +
• Patient with HCV active hepatitis are excluded from the study. Patient with no evidence of active hepatitis and/or advanced chronic liver disease according to liver biopsy or fibro-scan evaluation may be included into the study;
• Previous treatment with Lenalidomide if patient resulted primary refractory to Lenalidomide or interrupted Lenalidomide less than 12 months before enrollment to this study.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Mantle-Cell
• Mantle Cell Lymphoma

Intervention

Drug:
• Carfilzomib
Carfilzomib
• Lenalidomide
Lenalidomide
• Dexamethasone
Dexamethasone

Locations

Country	Name	City	State
Italy	ASST Spedali Civili di Brescia - Ematologia	Brescia
Italy	ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia	Milano
Italy	Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Ematologia	Milano
Italy	AOU Maggiore della Carità di Novara - SCDU Ematologia	Novara
Italy	IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia	Pavia
Italy	Ospedale delle Croci - Ematologia	Ravenna
Italy	AOU Senese - U.O.C. Ematologia	Siena
Italy	A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria	Torino
Italy	Azienda sanitaria-universitaria integrata Trieste (ASUITS) - SC Ematologia	Trieste
Italy	Azienda Sanitaria Universitaria Integrata di Udine (A.S.U.I. Udine) - SOC Clinica Ematologica	Udine
Italy	AOU Integrata di Verona - U.O. Ematologia	Verona

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione Italiana Linfomi ONLUS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Efficacy Endpoint - 12-months overall survival	12-month overall survival : probability of surviving from the date of beginning of therapy up to month 12 based on Kaplan-Meier estimator	The primary endpoint will be assessed 12 months after the start of treatment of the last patient.
Secondary	Secondary Endpoints 1 - ORR	overall response rate will be defined according to Lugano criteria. The best overall; response will be defined as the best response between the date of beginning of therapy and the last restaging. Patients without response assessment (due to whatever reason) will be considered as non-responders.	The endpoint will be assessed from the date of randomization to the date of the first documented progression, evaluated up to 12 months.
Secondary	Secondary Endpoints 1 - CR	complete response rate between the date of beginning of therapy and the last restaging. Patients without response assessment (due to whatever reason) will be considered as non-responders.	The endpoint will be assessed from the date of randomization to the date of the first documented progression, evaluated up to 12 months.
Secondary	Secondary Endpoints 1 - PR	partial response rate between the date of beginning of therapy and the last restaging. Patients without response assessment (due to whatever reason) will be considered as non-responders.	The endpoint will be assessed from the date of randomization to the date of the first documented progression, evaluated up to 12 months.
Secondary	Secondary Endpoints 1 - SD	rate between the date of beginning of therapy and the last restaging. Patients without response assessment (due to whatever reason) will be considered as non-responders.	The endpoint will be assessed from the date of randomization to the date of the first documented progression, evaluated up to 12 months.
Secondary	Secondary Endpoints 2 - PFS	progression-free survival will be defined as the time from beginning of therapy until lymphoma relapse or progression or death as a result of any cause; responding patients and patients who are lost to follow up will be censored at their last assessment date;	The endpoint will be assessed from the date of randomization to the date of the first documented progression, evaluated up to 12 months.
Secondary	Secondary Endpoints 3 - OS	overall survival will be defined as the time from beginning of therapy until death as a result of any cause; patients who are lost to follow up will be censored at their last assessment date;	through the completion of the study, an average of 1 year
Secondary	Secondary Endpoints 4 - TTR	time to response will be defined for all patients who achieved a response (Complete Response or Partial Response) and is measured from the date of beginning of therapy until the date of response. Patients in relapse or progression will be censored at their last assessment date. Patients death due to any cause will be consider censored or competing event according to different analysis plan	through the completion of the study, an average of 1 year
Secondary	Secondary Endpoints 5 - DoT	the duration of the treatment will be defined as the time from beginning of therapy until discontinuation due to any reason.	through the completion of the study, an average of 1 year